Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.95
(44.76%)
USD 43.95
(44.76%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 258.88 Billion JPY | 10.77% |
| 2022 | 250.38 Billion JPY | 4.45% |
| 2021 | 239.71 Billion JPY | 12.94% |
| 2020 | 212.25 Billion JPY | 1.31% |
| 2019 | 209.51 Billion JPY | 8.77% |
| 2018 | 192.61 Billion JPY | 6.36% |
| 2017 | 181.09 Billion JPY | 8.47% |
| 2016 | 166.95 Billion JPY | -2.83% |
| 2015 | 171.81 Billion JPY | 2.78% |
| 2014 | 167.17 Billion JPY | 5.85% |
| 2013 | 157.93 Billion JPY | 7.38% |
| 2012 | 147.07 Billion JPY | 34.49% |
| 2011 | 109.35 Billion JPY | 1.05% |
| 2010 | 108.22 Billion JPY | -0.45% |
| 2009 | 108.71 Billion JPY | -26.72% |
| 2008 | 148.34 Billion JPY | 5.35% |
| 2007 | 140.81 Billion JPY | 4.56% |
| 2006 | 134.67 Billion JPY | 3.02% |
| 2005 | 130.73 Billion JPY | -0.68% |
| 2004 | 131.63 Billion JPY | 23.95% |
| 2003 | 106.19 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 62.44 Billion JPY | -7.37% |
| 2024 Q2 | 68.25 Billion JPY | 11.53% |
| 2023 Q3 | 72.95 Billion JPY | 15.54% |
| 2023 Q4 | 67.41 Billion JPY | -7.59% |
| 2023 Q1 | 62.61 Billion JPY | -17.73% |
| 2023 FY | 277.34 Billion JPY | 10.77% |
| 2023 Q2 | 63.14 Billion JPY | 0.84% |
| 2022 Q4 | 76.11 Billion JPY | 28.35% |
| 2022 Q2 | 55.85 Billion JPY | -5.54% |
| 2022 Q1 | 59.12 Billion JPY | -18.62% |
| 2022 FY | 250.38 Billion JPY | 4.45% |
| 2022 Q3 | 59.3 Billion JPY | 6.18% |
| 2021 Q2 | 56.64 Billion JPY | 14.4% |
| 2021 Q1 | 49.51 Billion JPY | -22.94% |
| 2021 FY | 239.71 Billion JPY | 12.94% |
| 2021 Q4 | 72.64 Billion JPY | 19.27% |
| 2021 Q3 | 60.91 Billion JPY | 7.54% |
| 2020 Q1 | 45.74 Billion JPY | -28.02% |
| 2020 Q3 | 52.35 Billion JPY | 4.89% |
| 2020 FY | 212.25 Billion JPY | 1.31% |
| 2020 Q4 | 64.24 Billion JPY | 22.73% |
| 2020 Q2 | 49.91 Billion JPY | 9.11% |
| 2019 Q3 | 48.72 Billion JPY | -8.02% |
| 2019 Q2 | 52.96 Billion JPY | 19.6% |
| 2019 FY | 209.51 Billion JPY | 8.77% |
| 2019 Q1 | 44.28 Billion JPY | -25.07% |
| 2019 Q4 | 63.54 Billion JPY | 30.43% |
| 2018 Q3 | 44.03 Billion JPY | -0.49% |
| 2018 Q4 | 59.1 Billion JPY | 34.23% |
| 2018 Q2 | 44.24 Billion JPY | -2.18% |
| 2018 Q1 | 45.23 Billion JPY | -19.49% |
| 2018 FY | 192.61 Billion JPY | 6.36% |
| 2017 Q4 | 56.18 Billion JPY | 38.14% |
| 2017 Q2 | 46.27 Billion JPY | 21.92% |
| 2017 Q1 | 37.95 Billion JPY | -20.81% |
| 2017 FY | 181.09 Billion JPY | 8.47% |
| 2017 Q3 | 40.67 Billion JPY | -12.1% |
| 2016 FY | 166.95 Billion JPY | -2.83% |
| 2016 Q3 | 40.02 Billion JPY | -0.75% |
| 2016 Q2 | 40.33 Billion JPY | 4.32% |
| 2016 Q1 | 38.65 Billion JPY | -22.41% |
| 2016 Q4 | 47.93 Billion JPY | 19.74% |
| 2015 FY | 171.81 Billion JPY | 2.78% |
| 2015 Q4 | 49.82 Billion JPY | 17.91% |
| 2015 Q3 | 42.25 Billion JPY | 2.73% |
| 2015 Q2 | 41.13 Billion JPY | 6.59% |
| 2015 Q1 | 38.59 Billion JPY | -23.14% |
| 2014 Q3 | 40.68 Billion JPY | 4.78% |
| 2014 Q4 | 50.21 Billion JPY | 23.42% |
| 2014 FY | 167.17 Billion JPY | 5.85% |
| 2014 Q1 | 37.45 Billion JPY | -12.4% |
| 2014 Q2 | 38.82 Billion JPY | 3.66% |
| 2013 Q4 | 42.75 Billion JPY | 5.25% |
| 2013 Q3 | 40.62 Billion JPY | 2.61% |
| 2013 FY | 157.93 Billion JPY | 7.38% |
| 2013 Q1 | 34.96 Billion JPY | -49.74% |
| 2013 Q2 | 39.58 Billion JPY | 13.21% |
| 2012 FY | 147.07 Billion JPY | 34.49% |
| 2012 Q1 | 25.22 Billion JPY | -15.08% |
| 2012 Q4 | 69.57 Billion JPY | 160.79% |
| 2012 Q3 | 26.67 Billion JPY | 4.17% |
| 2012 Q2 | 25.6 Billion JPY | 1.54% |
| 2011 Q4 | 29.69 Billion JPY | 6.37% |
| 2011 FY | 109.35 Billion JPY | 1.05% |
| 2011 Q3 | 27.91 Billion JPY | 4.92% |
| 2011 Q1 | 25.13 Billion JPY | -13.26% |
| 2011 Q2 | 26.6 Billion JPY | 5.89% |
| 2010 Q4 | 28.97 Billion JPY | 8.76% |
| 2010 Q2 | 27.83 Billion JPY | 12.32% |
| 2010 Q1 | 24.77 Billion JPY | -28.46% |
| 2010 FY | 108.22 Billion JPY | -0.45% |
| 2010 Q3 | 26.63 Billion JPY | -4.3% |
| 2009 Q1 | 23.2 Billion JPY | 0.0% |
| 2009 Q3 | 25.86 Billion JPY | 3.43% |
| 2009 Q4 | 34.63 Billion JPY | 33.92% |
| 2009 FY | 108.71 Billion JPY | -26.72% |
| 2009 Q2 | 25 Billion JPY | 7.77% |
| 2008 FY | 148.34 Billion JPY | 5.35% |
| 2007 FY | 140.81 Billion JPY | 4.56% |
| 2006 FY | 134.67 Billion JPY | 3.02% |
| 2005 FY | 130.73 Billion JPY | -0.68% |
| 2004 FY | 131.63 Billion JPY | 23.95% |
| 2003 FY | 106.19 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | -775.269% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | -1416.531% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | -11958.296% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -507830.311% |
| Novartis AG | 24.87 Billion USD | -940.919% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 97.81% |